- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | Tariffs 'could cancel out discounts with biosimilars' | ||
| 17.04. | GSK reprimanded over "shocking error" in Omjjara info | ||
| 17.04. | There's good news for RSV jab firms at delayed ACIP meeting | ||
| 17.04. | Spruce Bio sows the seeds of its new future | ||
| 16.04. | FDA clears first migraine DTx from Click Therapeutics | ||
| 16.04. | Trump pledges drug price cuts - and action on 'pill penalty' | ||
| 16.04. | Trump pledges drug price cuts - and an end to 'pill penalty' | ||
| 16.04. | UK Biobank responds to fears over Chinese access to NHS data | ||
| 16.04. | J&J expecting $400m hit from tariffs in 2025 | ||
| 16.04. | After delay, Alzheimer's drug Leqembi gets green light in EU | ||
| 15.04. | Norgine on a growth charge again with Theravia takeover deal | ||
| 15.04. | Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma | ||
| 15.04. | Ironwood crashes down as FDA seeks new phase 3 trial | ||
| 15.04. | Failed trial knocks back wider use of BMS' Camzyos | ||
| 15.04. | US starts the clock ticking on pharma tariffs | ||
| 14.04. | Scancell taps into NHS matchmaking service for cancer trial | ||
| 14.04. | Pfizer's weight-loss aspirations are dealt a heavy blow | ||
| 14.04. | BMS gets another FDA okay for Opdivo/Yervoy combo | ||
| 14.04. | Why relying on AI outcome models may not be a good idea | ||
| 14.04. | Approval moves Columvi earlier in DLBCL treatment pathway | ||
| 11.04. | RFK Jr unorthodox vaccine views on show in interview | ||
| 11.04. | Pill that can slow breast cancer cleared for NHS use | ||
| 11.04. | Novartis plans $23bn manufacturing, R&D spend in US | ||
| 11.04. | FDA plans to phase out animal testing for antibodies | ||
| 11.04. | Alzheon Alzheimer's hopes dented by trial readout |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
